-
MyChart
Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
-
Request an Appointment
Request an Appointment
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information - Donate Today
Study #2015-0647
A Randomized Phase II Induction Discontinuation Trial of Emactuzumab following Paclitaxel and Bevacizumab in Patients with platinum-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer
Study Status
Open
Treatment Agent
Bevacizumab,Emactuzumab,Paclitaxel
Principal Investigator
Robert Coleman
Description
You are being asked to take part in this study because you have ovarian, fallopian tube, or primary peritoneal cancer that is relapsed (has come back) or refractory (has not responded to treatment). The goal of this clinical research study is to learn if adding emactuzumab to the combination of paclitaxel and bevacizumab can help to control relapsed or refractory ovarian, fallopian tube, or primary peritoneal cancer. The safety and side effects of this drug combination will also be studied.
General Information
Disease Group: Malignant neoplasms of female genital organs
Treatment Agent: Bevacizumab,Emactuzumab,Paclitaxel
Treatment Location: Both at MDACC & and Other Sites
Sponsor: Gateway for Cancer Research,Genentech Pharmaceuticals,Moonshots Program,Roche,The V Foundation for Cancer Research
Study Status
IRB Review and Approval Date: 05/05/2017
Recruitment Status: Open
Projected Accrual: 121
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Malignant neoplasms of female genital organs
Study phase:
Phase II
Physician name:
Robert Coleman
Department:
Gynecologic Oncology
For general questions about clinical trials:
1-877-632-6789